Ragaglitazar

Ragaglitazar

SCHEMBL682732

CCOC(Cc1ccc(OCCN2c3ccccc3Oc3ccccc32)cc1)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 18/20 1.00
PPARG P37231 17/20 1.00
PPARD Q03181 4/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ragaglitazar SCHEMBL676872 1.00 PPARA (1.00) PPARAPPARGPPARD
Ragaglitazar SCHEMBL4822459 1.00 PPARA (1.00) PPARAPPARGPPARD
Ragaglitazar SCHEMBL29369224 1.00 PPARA (1.00) PPARAPPARGPPARD
Ragaglitazar SCHEMBL6283531 0.95 PPARG (0.91) PPARAPPARGPPARD
Ragaglitazar SCHEMBL6283288 0.94 PPARG (0.89) PPARAPPARGPPARD
Ragaglitazar SCHEMBL6281839 0.94 PPARG (0.89) PPARAPPARGPPARD
Ragaglitazar SCHEMBL6281098 0.93 PPARG (0.86) PPARAPPARGPPARD
Ragaglitazar SCHEMBL6281101 0.93 PPARG (0.86) PPARAPPARGPPARD
Ragaglitazar SCHEMBL6820225 0.93 PPARG (0.86) PPARAPPARGPPARD
Ragaglitazar SCHEMBL6824727 0.93 PPARG (0.86) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338480-B2 Combination treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION (US) 2012-12-25 US claimed
WO-2012158123-A1 COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2012-11-22 WO claimed
US-20100292277-A1 COMBINATION TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2010-11-18 US claimed
EP-2001461-A2 COMBINATION TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2008-12-17 EP claimed
EP-1949908-A1 Combined use of derivatives of GLP-1 analogs and PPAR ligands NOVO NORDISK A/S (DK) 2008-07-30 EP claimed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US claimed
WO-2007117791-A2 COMBINATION TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-10-18 WO claimed
US-20050070536-A1 Novel tablets and capsules and a process for its preparation DR. REDDY'S LABORATORIES, INC. 2005-03-31 US claimed
EP-1370244-A1 NOVEL TABLETS AND CAPSULES AND A PROCESS FOR ITS PREPARATION NOVO NORDISK A/S (DK) 2003-12-17 EP claimed
EP-1368055-A2 COMBINED USE OF DERIVATIVES OF GLP-1 ANALOGS AND PPAR LIGANDS NOVO NORDISK A/S (DK) 2003-12-10 EP claimed
US-20020077320-A1 Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them DR. REDDY'S RESEARCH FOUNDATION AND REDDY- CHEMINOR, INC. 2002-06-20 US claimed
WO-2000063193-A9 NOVEL POLYMORPHIC FORMS OF AN ANTIDIABETIC AGENT: PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM REDDY RESEARCH FOUNDATION (IN) 2002-04-04 WO claimed
EP-1155006-A1 NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM Dr. Reddy's Research Foundation (IN) 2001-11-21 EP claimed
CN-1280575-A Novel tricyclic compounds and their use as medicaments, process for their preparation and pharmaceutical compositions containing them REDDY CHEMINOR INC (IN) 2001-01-17 CN claimed
EP-1049684-A1 NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 2000-11-08 EP claimed
WO-2000063191-A1 NOVEL POLYMORPHIC FORMS OF AN ANTIDIABETIC AGENT: PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 2000-10-26 WO claimed
WO-2000063193-A1 NOVEL POLYMORPHIC FORMS OF AN ANTIDIABETIC AGENT: PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 2000-10-26 WO claimed
WO-2000050414-A1 NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM DR.REDDY'S RESEARCH FOUNDATION (IN) 2000-08-31 WO claimed
US-6054453-A HYPOLIPIDEMIC, ANTIHYPERGLYCEMIC USES. REDD'S RESEARCH FOUNDATION (IN) 2000-04-25 US claimed
WO-1999019313-A1 NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-04-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases PPM1B, PPM1D, PTPRS PPARA 2456/4885PPARG 1818/4885PPARD 1972/4885
US-20100292277-A1 COMBINATION TREATMENT OF METABOLIC DISORDERS NR1H3, GPR119, NR1H2 PPARA 13/4885PPARG 12/4885PPARD 7/4885
US-20020077320-A1 Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them LIPC, GPR119, CPT1A PPARA 281/4885PPARG 102/4885PPARD 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.